Full-Time

Scientific Technical Lead

Late Stage CMC

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$109.5k - $208.5k/yr

+ Long-term incentive program

North Chicago, IL, USA

Hybrid

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
LLM
Scikit-learn
Dataiku
MLOps
Python
Data Science
TensorFlow
R
PyTorch
Apache Spark
Machine Learning
Data Engineering
RAG
Tableau
Pandas
NumPy

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Computer Science or a related discipline with 7 years of experience in IT and application program development, or a Master's degree with 6 years of experience, or a PhD with 2 years of experience.
  • Hands-on experience building and deploying data science or machine learning solutions in a scientific or engineering-intensive environment.
  • Expert-level Python proficiency and deep familiarity with the scientific Python ecosystem, including NumPy, pandas, scikit-learn, PyTorch or TensorFlow, cloud, big data, and pipeline orchestration.
  • A strong foundation in business analytics, with mastery of R, Dataiku, AWS SageMaker, Spark, and Tableau.
  • A strong foundation in data science methods, statistical modeling, experimental design, multivariate analysis, and uncertainty quantification, including the ability to choose, justify, and communicate methodological choices rigorously.
  • Familiarity with knowledge graphs, retrieval-augmented systems, or orchestrated artificial intelligence and large language model systems applied to scientific or technical domains.
  • Experience applying data science in a GxP-regulated environment, with working knowledge of FDA and EMA expectations for process validation, continued process verification, and control strategy.
  • Familiarity with MLOps principles, model lifecycle management, or deployment of analytical tools in regulated or enterprise environments.
  • Ability to define a problem space, drive solutions to completion, and remain accountable for outcomes.
  • Ability to evaluate solution landscapes and select fit-for-purpose tools and approaches.
  • Ability to build explainable, defensible, and improvable models and apply scientific integrity to analytical work.
  • Ability to earn the confidence of scientists, engineers, and quality professionals through credible and clear technical work.
  • Ability to address high-stakes analytical problems effectively amid ambiguity.
Responsibilities
  • Design, build, and deploy predictive and prescriptive models supporting process robustness assessment, control strategy optimization, and commercial process validation across late-stage biologics programs.
  • Develop multivariate and time-series modeling approaches to identify critical process parameter interactions, predict process drift, and support proactive deviation prevention at commercial manufacturing sites.
  • Apply dimensionality reduction, anomaly detection, Bayesian inference, and hybrid mechanistic-empirical models to characterize complex bioprocess behavior and establish process design spaces.
  • Build and maintain golden batch frameworks and optimization models serving as living benchmarks for process performance across sites and over time.
  • Lead the development of data infrastructure and analytical tools enabling data-driven technology transfer from development to commercial manufacturing.
  • Build cross-site process intelligence systems that enable teams to compare, contextualize, and act on process data across distributed sites and diverse equipment trains.
  • Partner with manufacturing science and quality teams to define data requirements, establish data standards, and ensure analytical continuity from process development through commercial operations.
  • Serve as a solution architect for AI and analytics initiatives within PDST, evaluating problems holistically and selecting appropriate statistical, machine learning, retrieval-augmented, orchestrated-agent, or hybrid approaches.
  • Establish modeling frameworks, validation protocols, and deployment standards that are scientifically rigorous, regulatory-aware, and maintainable in a GxP environment.
  • Contribute to PDST's AI roadmap by identifying high-value opportunities, scoping solutions, and advocating for infrastructure investments.
  • Define and drive data strategy for late-stage biologics programs, including data acquisition planning, ontology development, quality standards, and integration across LIMS, MES, historian, and electronic batch record systems.
  • Champion data literacy and modeling best practices across PDST and its manufacturing and quality stakeholder community.
  • Ensure models, analyses, and data assets are documented, version-controlled, and maintained consistently with regulatory expectations, including 21 CFR Part 11, ICH Q8/Q9/Q10, and FDA and EMA guidance.
  • Translate complex analytical outputs into clear, actionable scientific narratives for manufacturing, quality, regulatory, and executive audiences.
  • Influence technical decision-making without formal authority through scientific rigor, transparent methodology, and demonstrated business impact.
  • Mentor junior scientists and analysts within PDST and contribute to technical excellence and continuous improvement.
Desired Qualifications
  • An advanced degree such as an M.S. or Ph.D. in Data Science, Biostatistics, Chemical Engineering, Biochemical Engineering, or a closely related quantitative discipline.
  • Direct experience in biologics manufacturing, late-stage process development, or commercial bioprocess operations, including upstream cell culture or fermentation and/or downstream purification or formulation unit operations.
  • Exposure to stability program analytics, comparability assessments, or post-approval change management from a data and modeling perspective.
  • Experience working with data from laboratory and manufacturing systems such as LIMS, MES, DeltaV or historian systems, and electronic batch record platforms, and building scalable data pipelines for process analytics.
  • A track record of scientific communication through publications, regulatory submissions, technical reports, or equivalent work demonstrating the ability to convey complex analytical work clearly and credibly.
  • Familiarity with technology transfer workflows, process characterization study design, or commercial process validation in a biologics or pharmaceutical context.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.